Shots:

• Blueprint Medicines to acquire Lengo for $250M in cash in addition to $215M upon achievement of regulatory approval & sales-based milestones. The acquisition is expected to close in Q4’21
• The acquisition will bolster precision oncology therapies with the addition of Lengo’s LNG-451 in Blueprint's lung cancer pipeline for the treatment of NSCLC in patients with EGFR exon 20 insertion mutations
• The acquisition also delivers additional preclinical precision oncology programs & research tools while Blueprint will add in its compound library for drug discovery. Additionally, Lengo plans to submit an IND application for LNG-451 to the US FDA in Dec 2021, based on the preclinical data

Ref: PRNewswire | Image: Lengo